Edgewise Therapeutics Q3 Net Income $1.17 Billion on Sevasemten Sale Gain
Edgewise Therapeutics reported third quarter 2026 net income of $1,166.2 million, or $9.65 per diluted share, compared with a net loss of $40.7 million in the same period of 2025. The swing reflects a $1.348 billion gain on the July 2026 sale of the sevasemten program and muscular dystrophy business to Servier, while operating expenses were roughly flat year over year.
Key points
- Net income of $1,166.2 million ($9.65 per diluted share) versus a net loss of $40.7 million ($0.39 per share) in Q3 2025
- Gain on the sevasemten sale to Servier was $1.348 billion; the company received $1.396 billion in upfront cash at closing
- Research and development expenses were $31.6 million versus $37.5 million; general and administrative expenses rose to $14.6 million from $9.4 million
- Cash, cash equivalents and marketable securities were $1,743.9 million as of September 30, 2026
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.